Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 20/20 | 0.75 |
| ▸ | CDK2 | P24941 | 7/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.66 |
| ▸ | INSR | P06213 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311496 | 0.92 | IGF1R (0.75) | IGF1RCDK2KCNH2INSR | |
| SCHEMBL3311599 | 0.91 | IGF1R (0.64) | IGF1RCDK2KCNH2INSR | |
| SCHEMBL3316588 | 0.88 | IGF1R (0.64) | IGF1RCDK2KCNH2INSR | |
| SCHEMBL3311959 | 0.88 | IGF1R (0.75) | IGF1RCDK2KCNH2INSR | |
| SCHEMBL3313615 | 0.88 | IGF1R (0.84) | IGF1RCDK2KCNH2INSR | |
| SCHEMBL3318390 | 0.87 | IGF1R (0.76) | IGF1RCDK2KCNH2INSR | |
| SCHEMBL3312222 | 0.87 | IGF1R (0.76) | IGF1RCDK2KCNH2INSR | |
| SCHEMBL3316222 | 0.85 | IGF1R (1.00) | IGF1RCDK2KCNH2INSR | |
| SCHEMBL3315070 | 0.85 | IGF1R (0.73) | IGF1RCDK2KCNH2INSR | |
| SCHEMBL3313630 | 0.85 | IGF1R (0.73) | IGF1RCDK2KCNH2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910316-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | claimed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | claimed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | claimed |
| EP-1910316-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | claimed |
| US-7268154-B2 | Substituted triazole compounds | HOFFMAN-LA ROCHE INC. (US) | 2007-09-11 | — | — | US | claimed |
| WO-2007012579-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | WO | claimed |
| US-20070021475-A1 | Substituted triazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | claimed |
| EP-1910316-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| EP-1910316-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| US-7268154-B2 | Substituted triazole compounds | HOFFMAN-LA ROCHE INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2007012579-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021475-A1 | Substituted triazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021475-A1 | Substituted triazole derivatives | GPR3, GRIN3A, GRIK3 | IGF1R 1127/4885CDK2 2203/4885KCNH2 205/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | IGF1R 4384/4885CDK2 64/4885KCNH2 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.